Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Melanoma development: current knowledge on melanoma pathogenesis (CROSBI ID 297675)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Lugović-Mihić, Liborija ; Ćesić, Diana ; Vuković, Petra ; Novak Bilić, Gaby ; Šitum, Mirna ; Špoljar, Sanja Melanoma development: current knowledge on melanoma pathogenesis // Acta Dermatovenerologica Croatica, 27 (2019), 3; 163-168

Podaci o odgovornosti

Lugović-Mihić, Liborija ; Ćesić, Diana ; Vuković, Petra ; Novak Bilić, Gaby ; Šitum, Mirna ; Špoljar, Sanja

engleski

Melanoma development: current knowledge on melanoma pathogenesis

The pathogenic features of melanomas include growth and amplification of atypical melanocytes associated with several features (self-sufficiency of growth factors, insensitivity to growth inhibitors, evasion of cellular apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion, and metastasis). These melanoma pathogenic events can be triggered by activating oncogenes or inactivating tumor- suppressor genes by means of molecular mechanisms such as dotted mutations, deletions, and translocations or epigenetic mechanisms such as microRNA expression and promoter methylation. In melanomas, an analysis of the gene aberrations in the genome has led to the discovery of the complex interaction of signaling pathways. Progression of melanomas also involves genetic instability and selective growth of cells with favorable mutations. Additional factors include genetic predisposition, mutagenesis, and suppressed host immune response. Some of the most important signaling pathways involved in the pathogenesis of melanoma are the MAPK, PI3K/PTEN/AKT, and MITF signaling pathways. Obtaining insight into the biology of melanocytes and pathogenesis of melanomas is important for the development of a targeted therapy (such as vemurafenib, dabrafenib, trametinib) as well as the immunotherapy (e.g. pembrolizumab, nivolumab, ipilimumab), which has enabled a substantial breakthrough in the treatment of patients with melanoma.

melanoma ; pathogenesis ; signaling pathways ; mutations ; targeted therapy ; immunotherapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

27 (3)

2019.

163-168

objavljeno

1330-027X

1847-6538

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost